Your request will be referred to the appropriate U.S. Pharmaceuticals medical professional, such as a Cibinqo pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report a Cibinqo issue?
ONLINE FORMReport adverse event
Learn More
You can report a Cibinqo adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
samples
Request Cibinqo samples
Online Sample Form
Learn More
Is my patient elegible for Cibinqo samples?
Your rep will communicate with you how to receive samples, when you can receive samples, the amount and more.
How do I find out who my Cibinqo rep is?
Not sure who your local Cibinqo pharma rep is? Reach out to U.S. Pharmaceuticals and they can help you identify your rep.
prior authorization
Cibinqo Prior authorization resources
Complete Letter of Medical Necessity
NOT PROVIDED BY BRANDCoverage Authorization Request
NOT PROVIDED BY BRANDComplete Coverage Authorization appeals
NOT PROVIDED BY BRANDCoverage Authorization Appeal
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
Pfizer Dermatology Patient Access Enrollment Form
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
NOT PROVIDED BY BRANDReimbursement help (FRM) resources
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Cibinqo Financial assistance options
Co-pay savings program
commercial only
Enroll in Patient Savings Program
Download Co-Pay Card: HCP Office Only
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Bridge Program
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
Patient Assistance Program Enrollment Form
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Cibinqo Patient education
Getting started on Cibinqo
NOT PROVIDED BY BRANDInstructions For Use: Atopic Dermatitis (Eczema)
Patient toolkit
About Cibinqo
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Before and After
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
View How to Take Cibinqo
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Doctor Discussion Guide
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Cibinqo FAQs
Is there a pregnancy exposure registry for CIBINQO?Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770.
Is CIBINQO safe to use during pregnancy?Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. However, all pregnancies carry some risk of birth defects, loss, or other adverse outcomes. Pregnant women should consult with their healthcare provider before using CIBINQO.
Is it safe to breastfeed while using CIBINQO?No data is available on the presence of abrocitinib in human milk, the effects on the breast-fed infant, or the effects on milk production. Because of the serious adverse findings in adults, including risks of serious infections, malignancy, and thrombosis, advise women not to breastfeed during treatment with CIBINQO and for one day after the last dose.
Can CIBINQO impair female fertility?Based on findings in rats, oral administration of CIBINQO may impair female fertility. Impaired fertility in female rats was reversible 1 month after cessation of abrocitinib oral administration. Women who are trying to conceive should consult with their healthcare provider before using CIBINQO.
Is CIBINQO safe for pediatric patients?The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or more with atopic dermatitis has been established. The safety and effectiveness of CIBINQO have not been established in pediatric patients below 12 years of age. In addition, irreversible bone findings have been observed in juvenile animal toxicity studies in rats. Parents or guardians of pediatric patients should consult with their healthcare provider before using CIBINQO.
Is CIBINQO safe for geriatric patients?Clinical trials of CIBINQO did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. However, a higher proportion of patients 65 years of age and older discontinued from clinical trials compared to younger patients, and they may be at increased risk of certain adverse reactions. Geriatric patients should consult with their healthcare provider before using CIBINQO.
What should I know about using CIBINQO if I have renal impairment?In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30–59 mL/min) renal impairment, the combined exposure of abrocitinib and its active metabolites is increased compared to patients with normal renal function. This may increase the risk of adverse reactions such as infections. CIBINQO is not recommended for use in patients with severe renal impairment and ESRD including those on renal replacement therapy. A dosage reduction is recommended in patients with moderate renal impairment, and no dosage adjustment is required in patients with mild renal impairment.
Can I use CIBINQO if I have hepatic impairment?CIBINQO is not recommended for use in patients with severe (Child Pugh C) hepatic impairment. Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment based on similar combined exposure of abrocitinib and its active metabolites compared to patients with normal hepatic function. In clinical trials, CIBINQO was not evaluated in patients with severe hepatic impairment.
What should I know about using CIBINQO if I am a CYP2C19 poor metabolizer?In patients who are CYP2C19 poor metabolizers, the exposure of abrocitinib is increased due to reduced metabolic clearance. Dosage reduction of CIBINQO is recommended in patients who are known or suspected to be CYP2C19 poor metabolizers based on genotype or previous history/experience with other CYP2C19 substrates.
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.